UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Tesco is the UK’s biggest grocer again — and its FY26 results explain exactly why Aldi and Lidl should be paying attention
Read More Pharma Industry News Theravance Biopharma (NASDAQ: TBPH) drops rare disease drug after Phase 3 failure triggers strategic review Theravance Biopharma drops its rare disease drug after a Phase 3 failure. Explore what this means for NASDAQ: TBPH and biotech investors. byPallavi MadhirajuMarch 3, 2026